BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22689924)

  • 1. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
    McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
    J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
    McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
    Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
    Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
    BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
    McCluskey AG; Boyd M; Pimlott SL; Babich JW; Gaze MN; Mairs RJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S28-35. PubMed ID: 18819996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
    Mairs RJ; Ross SC; McCluskey AG; Boyd M
    J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
    McCluskey AG; Boyd M; Gaze MN; Mairs RJ
    Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
    D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
    Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
    Rae C; Tesson M; Babich JW; Boyd M; Mairs RJ
    EJNMMI Res; 2013 Nov; 3(1):73. PubMed ID: 24219987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
    Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
    Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
    Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
    Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
    Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
    J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
    J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
    Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
    Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
    Montariello D; Troiano A; Di Girolamo D; Beneke S; Calabrò V; Quesada P
    Biochem Pharmacol; 2015 Apr; 94(3):212-9. PubMed ID: 25667043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
    Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
    Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
    Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
    Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
    Kraal KC; Tytgat GA; van Eck-Smit BL; Kam B; Caron HN; van Noesel M
    Pediatr Blood Cancer; 2015 Nov; 62(11):1886-91. PubMed ID: 25981988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
    Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
    Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.